

**Remarks**

Claims 1, 6-10, 12-14, 29, 34-39, 44-49, and 59-68 are pending in the present application. Claims 1, 13, and 14 were previously amended in the response dated October 7, 2004. Please cancel claims 49, 59-68 without prejudice to applicants' right to pursue patent protection for the cancelled subject matter in a later filed divisional or continuation application. The above amendment adds no new matter to this application.

Applicants respectfully request entry of this Amendment and reconsideration of the application as amended.

**Enablement Rejection Under 35 U.S.C. §112, first paragraph for Claims 49 and 59-68**


On pages 2-7 of the April 25, 2005 Action the Examiner has rejected claims 49, and 59-68 under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the enablement requirement. The Examiner asserts that the claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is mostly nearly connected, to make and/or use the invention.

Applicants do not concede that the rejected claims of the subject application are not enabled, however, in the interest of expediting the prosecution of the subject application applicants have hereinabove canceled claims 49, 59-68. Examiner's rejections are thus rendered moot.

**Conclusion**

For the reasons set forth hereinabove, applicants respectfully request that the Examiner reconsider and withdraw the various grounds for rejection set forth in the April 25, 2005 Office Action and earnestly solicit allowance of the claims pending in the subject application.

Respectfully submitted,

  
Garth Butterfield  
Attorney for Applicants  
Reg. No. 36,997

Date: May 20, 2005

Pfizer Inc.  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-5310